Myelofibrosis and Polycythemia Vera: Current and Emerging Treatment Options

This comprehensive program gathers insight from 5 experts to improve the skills of clinicians who treat patients with myeloproliferative neoplasms, particularly myelofibrosis and polycythemia vera. All aspects of this program are designed to complement each other, including an Interactive Treatment Decision Support Tool, an expert-authored commentary and module, and a downloadable slideset.
Brady L. Stein, MD, MHS

ClinicalThought

In this commentary, I highlight study findings from the 2016 Hematology meeting that may affect management of patients with myelofibrosis or polycythemia vera.

Brady L. Stein, MD, MHS Released: December 30, 2016
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Incyte

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue